Biotech and Pharmaceuticals Pharmaceuticals

More

  • LONDON, July 27- GlaxoSmithKline plans 275 million pounds of new investments at three drug manufacturing sites in Britain, signaling its confidence in the country despite last month's vote to leave the European Union.

  • The Associated Press reported Monday that it appears Arkansas had obtained a paralytic drug made by a subsidiary of Pfizer for use in executions. Pfizer has said it doesn't want its drugs used that way and that it has safeguards in place to prevent it from happening. Doug House, a Republican from North Little Rock, said Tuesday that while Pfizer may complain about...

  • EXCLUSIVE- ISRAEL'S TEVA, UK'S MYLAN, INDIA'S SUN PHARMACEUTICAL EYE PFIZER'S BRAZILIAN GENERIC DRUG VENTURE TEUTO, SOURCES SAY.

  • SAO PAULO, July 26- Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said. Brazil's Melo family owns the remaining 60 percent of Teuto 5/ 8 Pfizer, Latin America's largest pharmaceutical plant.

  • EXCLUSIVE-PROCESS TO SELL BRAZILIAN GENERIC DRUGMAKER TEUTO, IN WHICH PFIZER HAS 40 PCT STAKE, IS IN EARLY STAGES, SOURCES SAY.

  • Eli Lilly CEO: Keep drug prices in perspective

    John Lechleiter, Eli Lily CEO, breaks down the company's quarterly results which reported EPS of $0.86 Adj on revenues of $5.40 billion. Also Lechleiter provides an update on new drug approvals and weighs in on drug pricing.

  • Revenue rose 8.6 percent to $5.4 billion in the second quarter, topping Wall Street estimates of $5.15 billion, as demand increased for its drugs including Trulicity, Cyramza and Humalog. The 140- year-old U.S. drugmaker said its net income rose 24.5 percent to $747.7 million, or 71 cents per share, in the quarter ended June 30. Excluding special items, Lilly earned...

  • July 26- Eli Lilly and Co reported a 24.5 percent jump in quarterly profit, driven by demand for its newer treatments for diabetes and cancer. The 140- year-old U.S. drugmaker said its net income rose to $747.7 million, or 71 cents per share, in the second quarter ended June 30, from $600.8 million, or 56 cents per share, a year earlier. Revenue rose 8.6 percent to $5.4...

  • TOKYO, July 26- Takeda Pharmaceutical Co Ltd will accept initial bids for its 70 percent stake in a chemicals company through Aug. 16, with potential suitors including CVC Capital Partners Ltd and Carlyle Group Ltd, sources told Reuters. Takeda, Japan's largest drugmaker by market value, aims to sell its holding in Wako Pure Chemicals Industries Ltd to streamline...

  • LITTLE ROCK, Ark.— An execution drug obtained by the Arkansas prison system earlier this month appears to have been made by a subsidiary of Pfizer, even though the pharmaceutical giant has said it doesn't want its drugs to be used in executions. It matches labels submitted to the National Institutes of Health by Hospira, Inc., which Pfizer bought last year.

  • Active Ownership Capital, which controls a stake of around 7 percent in Stada, wants to oust chairman Martin Abend and install international pharmaceutical experts at the company's annual general meeting on Aug. 26. In a statement on Monday, Active Ownership said it opposed current members Martin Abend, Carl Ferdinand Oetker and two prospective new members,...

  • Active Ownership Capital, which controls a stake of around 7 percent in Stada, wants to oust chairman Martin Abend and install international pharmaceutical experts at the company's annual general meeting on August 26.

  • Yee: Biotech stocks will outperform after election

    Les Funtleyder, E Squared asset management, and Michael Yee, RBC biotech analyst, discuss trading health care and the future of biotech during the election.

  • Bracing for a 'bio-wreck'?

    Though the biotech sector has had a sharp turnaround since mid June, is the worst really over? The "Fast Time Halftime Report" traders discuss whether or not its worth buying the biotech bounce.

  • WASHINGTON— A safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of dollars for pricey medications at taxpayer expense, government numbers show. The cost of Medicare's "catastrophic" prescription coverage jumped by 85 percent in three years, from $27.7 billion in 2013 to $51.3 billion in 2015, according to the program's...

  • WASHINGTON— A safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of dollars for pricey medications at taxpayer expense, government numbers show. The cost of Medicare's "catastrophic" prescription coverage jumped by 85 percent in three years, from $27.7 billion in 2013 to $51.3 billion in 2015, according to the program's...

  • IT Cosmetics product

    Cosmetics company L'Oreal has agreed to buy IT Cosmetics for $1.2 billion.

  • Regeneron Pharmaceuticals

    Big drug discoveries have been scant, but investors can find long-term value in some biotech names, said Mark Schoenebaum of Evercore ISI.

  • Patrick Swailes Caldwell rehearses his character of “Martin Shkreli” for the Manhattan premiere of the musical “Martin Shkreli’s Game: How Bill Murray Joined the Wu-Tang Clan”

    The campy, song-laden take on the indicted pharmaceutical exec features portrayals of the Wu-Tang Clan, Bill Murray ... and a ghost.

  • July 21- Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study. There were no "clinically meaningful" differences in data gathered from patients given Herceptin and the copycat version, ABP 980, to treat a type of early breast cancer, said...